An alternate binding site for PPARÎ 3 ligands

Nature Communications

Volumn 5, Issue , 2014, Pages

  Hughes, Travis S ^a   Giri, Pankaj Kumar ^a   De Vera, Ian Mitchelle S ^a   Marciano, David P ^a   Kuruvilla, Dana S ^a   Shin, Youseung ^a   Blayo, Anne Laure ^a   Kamenecka, Theodore M ^a   Burris, Thomas P ^a   Griffin, Patrick R ^a   Kojetin, Douglas J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

CANONICAL ANALYSIS; CHEMICAL BINDING; DIABETES; DRUG; GENE EXPRESSION; LIGAND;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; TRANSACTIVATION; CHEMISTRY; METABOLISM;

BINDING SITES; LIGANDS; PPAR GAMMA;

EID: 84904364314     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4571     Document Type: Article

References (66)

1. Nwachukwu, J. C., Nettles, K. W. The nuclear receptor signalling scaffold: insights from full-length structures. EMBO J. 31, 251-253 (2012).
2. Chandra, V. et al. Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex. Nature 495, 394-398 (2013).
3. Chandra, V. et al. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA. Nature 456, 350-356 (2008).
4. Orlov, I., Rochel, N., Moras, D., Klaholz, B. P. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J. 31, 291-300 (2012).
5. Rochel, N. et al. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat. Struct. Mol. Biol. 18, 564-570 (2011).
6. Zhang, J. et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat. Struct. Mol. Biol. 18, 556-563 (2011).
7. Moore, J. T., Collins, J. L., Pearce, K. H. The nuclear receptor superfamily and drug discovery. Chem. Med. Chem. 1, 504-523 (2006).
8. Renaud, J. P. et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689 (1995).
9. Nagy, L., Schwabe, J. W. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29, 317-324 (2004).
10. Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-481 (2011).
11. Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451-456 (2010).
12. Hughes, T. S. et al. Ligand and receptor dynamics contribute to the mechanism of graded PPARg agonism. Structure 20, 139-150 (2012).
13. Bruning, J. B. et al. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15, 1258-1271 (2007).
14. Waku, T. et al. The nuclear receptor PPARgamma individually responds to serotonin-and fatty acid-metabolites. EMBO J. 29, 3395-3407 (2010).
15. Acton, 3rd J. J. et al. Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 15, 357-362 (2005).
16. Riepl, H. et al. Sequential backbone assignment of peroxisome proliferatoractivated receptor-gamma ligand binding domain. J. Biomol. NMR 32, 259 (2005).
17. Kleckner, I. R., Foster, M. P. An introduction to NMR-based approaches for measuring protein dynamics. Biochim. Biophys. Acta 1814, 942-968 (2011).
18. Aci-Seche, S., Genest, M., Garnier, N. Ligand entry pathways in the ligand binding domain of PPARgamma receptor. FEBS Lett. 585, 2599-2603 (2011).
19. Genest, D. et al. Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations. Eur. Biophys. J. 37, 369-379 (2008).
20. Leesnitzer, L. M. et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650 (2002).
21. Lee, G. et al. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 277, 19649-19657 (2002).
22. Reibarkh, M., Malia, T. J., Wagner, G. NMR distinction of single-and multiple-mode binding of small-molecule protein ligands. J. Am. Chem. Soc. 128, 2160-2161 (2006).
23. Lamotte, Y. et al. Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 20, 1399-1404 (2010).
24. Shiraki, T. et al. Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 280, 14145-14153 (2005).
25. Soares, A. F. et al. Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma. Biochem. Biophys. Res. Commun. 337, 521-525 (2005).
26. Itoh, T. et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 15, 924-931 (2008).
27. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956 (1995).
28. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395, 137-143 (1998).
29. Forman, B. M. et al. 15-Deoxy-D12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARg. Cell 83, 803-812 (1995).
30. Kliewer, S. A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
31. Li, Y. et al. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat. Struct. Mol. Biol. 15, 865-867 (2008).
32. Waku, T. et al. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. J. Mol. Biol. 385, 188-199 (2009).
33. Waku, T., Shiraki, T., Oyama, T., Morikawa, K. Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands. FEBS Lett. 583, 320-324 (2009).
34. Rogue, A. et al. Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in human hepatocytes. PLoS One 6, e18816 (2011).
35. Hurtado, O. et al. Daidzein has neuroprotective effects through ligand-bindingindependent PPARgamma activation. Neurochem. Int. 61, 119-127 (2012).
36. Sikka, S., Chen, L., Sethi, G., Kumar, A. P. Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Res. 2012, 968040 (2012).
37. Akinyeke, T. O., Stewart, L. V. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgamma-independent mechanism. Cancer Biol. Ther. 11, 1046-1058 (2011).
38. Lyles, B. E., Akinyeke, T. O., Moss, P. E., Stewart, L. V. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 8, 268-277 (2009).
39. Robbins, G. T., Nie, D. PPAR gamma, bioactive lipids, and cancer progression. Front. Biosci. 17, 1816-1834 (2012).
40. Lea, M. A., Sura, M., Desbordes, C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists. Anticancer Res. 24, 2765-2771 (2004).
41. Nettles, K. W. Insights into PPARgamma from structures with endogenous and covalently bound ligands. Nat. Struct. Mol. Biol. 15, 893-895 (2008).
42. Li, Y. et al. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. J. Biol. Chem. 283, 9168-9176 (2008).
43. Moore, T. W., Mayne, C. G., Katzenellenbogen, J. A. Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol. Endocrinol. 24, 683-695 (2010).
44. Wang, Y. et al. A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor b. Proc. Natl Acad. Sci. USA 103, 9908-9911 (2006).
45. Kojetin, D. J., Burris, T. P., Jensen, E. V., Khan, S. A. Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocr. Relat. Cancer 15, 851-870 (2008).
46. Jensen, E. V., Khan, S. A. A two-site model for antiestrogen action. Mech. Ageing Dev. 125, 679-682 (2004).
47. Buzon, V., Carbo, L. R., Estruch, S. B., Fletterick, R. J., Estebanez-Perpina, E. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol. Cell Endocrinol. 348, 394-402 (2012).
48. Grosdidier, S. et al. Allosteric conversation in the androgen receptor ligand-binding domain surfaces. Mol. Endocrinol. 26, 1078-1090 (2012).
49. Estébanez-Perpinã, E. et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl Acad. Sci. USA 104, 16074-16079 (2007).
50. Estébanez-Perpinã, E. et al. Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol. Endocrinol. 21, 2919-2928 (2007).
51. Arnold, L. A. et al. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. 280, 43048-43055 (2005).
52. Sadana, P. et al. Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem. Biol. 6, 1096-1106 (2011).
53. Mizwicki, M. T. et al. Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha,25(OH)2-vitamin D3 signaling. Proc. Natl Acad. Sci. USA 101, 12876-12881 (2004).
54. Mizwicki, M. T., Bula, C. M., Bishop, J. E., Norman, A. W. New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. J. Steroid Biochem. Mol. Biol. 103, 243-262 (2007).
55. Mizwicki, M. T., Bula, C. M., Bishop, J. E., Norman, A. W. A perspective on how the Vitamin D sterol/Vitamin D receptor (VDR) conformational ensemble model can potentially be used to understand the structure-function results of A-ring modified Vitamin D sterols. J. Steroid Biochem. Mol. Biol. 97, 69-82 (2005).
56. Mizwicki, M. T., Norman, A. W. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci. Signal. 2, re4 (2009).
57. Menegaz, D. et al. Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Mol. Endocrinol. 25, 1289-1300 (2011).
58. Motani, A. et al. INT131: a selective modulator of PPAR gamma. J. Mol. Biol. 386, 1301-1311 (2009).
59. Solt, L. A. et al. Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. Nature 485, 62-68 (2012).
60. Findeisen, M., Brand, T., Berger, S. A 1H-NMR thermometer suitable for cryoprobes. Magn. Reson. Chem. 45, 175-178 (2007).
61. Otten, R., Chu, B., Krewulak, K. D., Vogel, H. J., Mulder, F. A. Comprehensive and cost-effective NMR spectroscopy of methyl groups in large proteins. J. Am. Chem. Soc. 132, 2952-2960 (2010).
62. Kovrigin, E. L. NMR line shapes and multi-state binding equilibria. J. Biomol. NMR 53, 257-270 (2012).
63. Chalmers, M. J. et al. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal. Chem. 78, 1005-1014 (2006).
64. Busby, S. A., Chalmers, M. J., Griffin, P. R. Improving digestion efficiency under H/D exchange conditions with activated pepsinogen coupled columns. Int. J. Mass. Spectrom. 259, 130-139 (2007).
65. Pascal, B. D. et al. HDX workbench: software for the analysis of H/D exchange MS data. J. Am. Soc. Mass. Spectrom. 23, 1512-1521 (2012).
66. Trott, O., Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).